Brind.

Synopsys and Alnylam Pharmaceuticals were operating and trading within the U.S. stock market on August 19, 2025.

1 report, 1 independent Updated Aug 19

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Synopsys Alnylam Pharmaceuticals

Keep exploring

The entities involved

Synopsys
American software company
- Synopsys and Alchip developed AI data center ASICs featuring high-speed SerDes.Mon 07:44
- Synopsys acquired ANSYS for $34.9 billion, and the companies are now collaborating on AI workflows with AMD and Microsoft.Sun 22:23
Alnylam Pharmaceuticals
biopharmaceutical company
- AstraZeneca's trial failure has created a competitive advantage for Alnylam Pharmaceuticals, which is leveraging AI in its commercial execution.Mon 11:04
- Alnylam Pharmaceuticals, SEC, Truist Financial, and Nasdaq were involved in insider trading disclosures, analyst ratings, and stock trading on June 6, 2026.Sun 17:03

Coverage

Newest first; wire copies grouped

Aug 19Simply Wall St.Three Companies That Might Be Priced Below Their Estimated Value As the U.S. stock market hovers near record highs, investors are closely watching for signals from the Federal Reserve and upcoming re